# Influenza Tests Devices Market

> Influenza Tests Devices Market Research Report Information By Tests (Influenza Multiplex NAATs, Influenza Antigen Tests, and Influenza Lowplex Nucleic Acid Amplification Tests (NAATs)), And By Region (North America, Europe, Asia-Pacific, And Rest of The World) –Market Forecast Till 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 7.0%
- **2024:** $ 0.44 Billion
- **2025:** $ 0.47 Billion
- **2035:** $ 0.92 Billion
- **Key Players:** Abbott (US), Roche (CH), Thermo Fisher Scientific (US), BD (US), Siemens Healthineers (DE), QuidelOrtho (US), Hologic (US), Cepheid (US), BioMerieux (FR)

**Report ID:** MRFR/HC/14563-HCR · **Pages:** 128 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** May 15, 2026

**URL:** https://www.marketresearchfuture.com/reports/influenza-tests-devices-market-16090

---

## Market Summary

## **Global Influenza Tests Devices Market Overview**

As per MRFR analysis, the Influenza Tests Devices Market Size was estimated at 0.44 (USD Billion) in 2024. The Influenza Tests Devices Market Industry is expected to grow from 0.47 (USD Billion) in 2025 to 0.86 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 7.00% during the forecast period (2025 - 2034). The increasing prevalence of influenza, the emergence of technologically advanced influenza diagnostics, and the growth in research funding for influenza diagnostics are expected to be a significant market driver for the Influenza Tests Devices Market.

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

## **Influenza Tests Devices Market Trends**

### **Rising prevalence of influenza and the growing geriatric population is driving the market growth**

Market CAGR for Influenza Tests Devices is being driven by the rising prevalence of influenza and the growing geriatric population. Epidemic influenza poses a significant public health challenge each season. The World Health Organization (WHO) estimates that influenza has a severe impact on three to five million individuals annually, resulting in 250,000 to 500,000 deaths. Children experience the highest attack rate, while complications such as hospitalization and death are most prevalent in the elderly.

The increasing geriatric population raises the likelihood of a higher incidence of flu. Consequently, the WHO recommends vaccination for individuals aged 65 and above to prevent influenza cases. According to the Centers for Disease Control and Prevention, the U.S. witnessed 9 million flu cases, 4 million influenza-related medical visits, 100,000 flu-related hospitalizations, and 5,000 flu-related deaths during the 2021–2022 season. Similar to previous seasons preceding the COVID-19 outbreak, 83% of fatalities were among older individuals. The weakened immune system of older adults makes them more susceptible to the flu virus.

As a result, it is anticipated that throughout the projection period, demand for the Influenza Tests Devices Market will increase due to the rising prevalence of influenza, and the growing geriatric population. Thus, driving the Influenza Tests Devices Market revenue.

## **Influenza Tests Devices Market Segment Insights**

### **Influenza Tests Devices Market Tests Insights**

 The Influenza Tests Devices Market segmentation, based on Tests includes Influenza Multiplex NAATs, Influenza Antigen Tests, and Influenza Lowplex Nucleic Acid Amplification Tests (NAATs). The influenza multiplex NAATs segment dominated the market, accounting for 58% of market revenue (0.06 Billion). Second-generation Nucleic Acid Amplification Tests (NAATs) typically exhibit enhanced sensitivity, often surpassing 95%, and offer rapid test times ranging from 5 to 90 minutes.

The potential advantages of rapid NAAT Point-of-Care Tests (POCTs) for individuals include early initiation of antiviral treatment, with optimal benefits observed when administered within 48 hours, as well as a reduction in the unnecessary use of antibiotics, minimizing exposure to unwanted side effects for patients.

**Figure 1: Influenza Tests Devices Market, by Tests, 2022 & 2032 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

### **Influenza Tests Devices Market Regional Insights**

By region, the study provides market insights into North America, Europe, Asia-Pacific, and Rest of the World. The anticipated expansion of the Influenza test devices market in North America can be attributed to several key factors. The rising disease prevalence in the U.S. is anticipated to propel market expansion. According to the Centers for Disease Control and Prevention (CDC), the 2021-2022 influenza season resulted in 9 million illnesses, 4 million medical visits, 10,000 hospitalizations, and 5,000 fatalities. The flu season occurred in two waves, with the second wave experiencing a higher number of hospitalizations.

The expected rise in awareness regarding the significance of flu vaccinations and early detection is also poised to foster market expansion.

Further, the major countries studied in the market report are the US, Canada, Germany, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

**Figure 2: INFLUENZA TESTS DEVICES MARKET SHARE BY REGION 2022 (USD Billion)**

****

Source: Secondary Research, Primary Research, _Market Research Future_ Database and Analyst Review

Europe's Influenza Tests Devices Market accounts for the second-largest market share as the anticipated high prevalence of influenza is set to be a driving factor for the regional market throughout the forecast period. In the 2022−2023 season, sentinel primary care providers in the EU/EEA tested 81,800 specimens for the influenza virus, with 19,538 (24%) testing positive. This marked a more than four-fold increase in influenza virus detections from sentinel sources compared to the 2021−2022 season and represented the highest number of detections over the past four seasons.

For instance, during the pre-pandemic season of 2019−2020, a total of 11,978 specimens tested positive. Further, the German Influenza Tests Devices Market held the largest market share, and the UK Influenza Tests Devices Market was the fastest-growing market in the European region

The Asia-Pacific Influenza Tests Devices Market is expected to grow at the fastest CAGR from 2023 to 2032. The regional market is poised for rapid growth, driven by increasing awareness and acceptance of influenza diagnostic kits. In 2021, the incidence of influenza virus infections in China declined significantly to approximately 47.4 per 100,000 people from the peak observed in 2019. Notably, the Ministry of Health, Labor, and Welfare released figures for September 11–17, based on reports from 5,000 designated medical institutions, revealing 34,665 influenza cases—an increase of 1.57 times compared to the previous week, averaging 7.03 cases per institution.

Additionally, the growing governmental support for the approval of new diagnostic tests for influenza contributes to the expansion of the influenza diagnostics market in the Asia-Pacific region. Moreover, China’s Influenza Tests Devices Market held the largest market share, and the Indian Influenza Tests Devices Market was the fastest-growing market in the Asia-Pacific region.

## **Influenza Tests Devices Market Key Market Players & Competitive Insights**

Leading market players are investing heavily in research and development to expand their product lines, which will help the Influenza Tests Devices market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the Influenza test devices industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the Influenza test devices industry to benefit clients and increase the market sector. In recent years, the Influenza test devices industry has offered some of the most significant advantages to the healthcare sector, enabling rapid and accurate diagnosis of influenza infections, leading to timely treatment and effective management of the disease. Major players in the Influenza Tests Devices Market, including Abbott Laboratories, Danaher Corp, Quidelortho Corp, bioMerieux SA, Sekisui Diagnostics LLC, F.

Hoffmann-La Roche Ltd, DiaSorin SpA, Becton Dickinson and Co, Qiagen NV, and Thermo Fisher Scientific Inc are attempting to increase market demand by investing in research and development operations.

Thermo Fisher Scientific Inc (Thermo Fisher) is a provider of medical equipment, analytical instruments, reagents, and consumables, as well as software and services addressing complex analytical challenges in research, diagnostics, and clinical laboratories. The company offers solutions in cellular analysis, biology, flow cytometry, and synthetic biology, with a product range covering mass spectrometry, genetic sequencing, electron microscopy, protein, and molecular biology research. Thermo Fisher serves diverse sectors including pharmaceutical and biotech companies, academic and research institutions, clinical diagnostic labs, and government agencies, along with the environmental, industrial quality, and process control sectors.

Its distribution channels include direct sales, e-commerce, and third-party distributors across the Americas, Asia-Pacific, and Europe. Headquartered in Waltham, Massachusetts, USA, Thermo Fisher Scientific acquired Mesa Biotech, a leading developer and manufacturer of next-generation molecular diagnostic tests, in January 2021 for USD 450 million. This strategic acquisition enhances Thermo Fisher Scientific's test portfolio by incorporating Mesa's PCR-based Accula rapid point-of-care test platform for SARS-CoV-2, RSV, Influenza A and B, and Strep A

Becton Dickinson and Co. (BD) is a medical technology company specializing in the manufacturing and sale of [medical devices](../../../reports/pediatric-medical-device-market-980), reagents, and instruments. Its diverse product portfolio includes syringes, pen needles, intravenous catheters, infusion pumps, automated medication dispensing systems, respiratory ventilation equipment, diagnostic tools, and more. BD caters to various sectors, including life science researchers, healthcare institutions, clinical laboratories, the pharmaceutical industry, and the general public. The company operates globally, with a presence in the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Headquartered in New Jersey, USA, BD recently received emergency use authorization from the U.S.

Food and Drug Administration in February 2023 for a novel molecular diagnostic combo test targeting influenza A + B, aiming to address diseases during the current and upcoming respiratory virus seasons.

### **Key companies in the Influenza Tests Devices Market include**

- [Abbott Laboratories](https://www.globalpointofcare.abbott/us/en/product-details/id-now-influenza-ab-2.html)
- Danaher Corp
- Quidelortho Corp
- bioMerieux SA
- [Sekisui Diagnostics LLC](https://sekisuidiagnostics.com/product/osom-ultra-plus-flu-ab-test/)
- F. Hoffmann-La Roche Ltd
- DiaSorin SpA
- Becton Dickinson and Co
- Qiagen NV
- Thermo Fisher Scientific Inc

## **Influenza Tests Devices Market Industry Developments**

- **Q2 2024: QuidelOrtho receives FDA clearance for Sofia 2 SARS Antigen FIA for use with nasal swab specimens** QuidelOrtho announced FDA clearance for its Sofia 2 SARS Antigen FIA, which can be used for rapid detection of influenza and SARS-CoV-2 from nasal swab specimens, expanding its diagnostic portfolio.
- **Q2 2024: Roche launches cobas® Influenza A/B & RSV test on the cobas® Liat® System in the US** Roche introduced its new cobas® Influenza A/B & RSV test for the cobas® Liat® System, providing rapid molecular results for influenza and RSV, aimed at improving point-of-care diagnostics in the US.
- **Q2 2024: BD Receives CE Mark for BD MAX™ Influenza A/B Test** BD (Becton, Dickinson and Company) received CE Mark approval for its BD MAX™ Influenza A/B test, enabling broader European market access for its molecular diagnostic platform.
- **Q3 2024: Abbott launches Alinity m Resp-4-Plex assay for detection of SARS-CoV-2, influenza A/B, and RSV** Abbott announced the launch of its Alinity m Resp-4-Plex assay, a multiplex molecular test that simultaneously detects SARS-CoV-2, influenza A/B, and RSV, expanding its respiratory diagnostics portfolio.
- **Q3 2024: QuidelOrtho announces partnership with CDC for influenza surveillance using rapid diagnostic tests** QuidelOrtho entered a partnership with the CDC to provide rapid influenza diagnostic tests for national surveillance programs, aiming to improve real-time tracking of flu outbreaks.
- **Q4 2024: Roche opens new diagnostics manufacturing facility in Indianapolis** Roche Diagnostics inaugurated a new manufacturing facility in Indianapolis to increase production capacity for its influenza and respiratory diagnostic test kits.
- **Q4 2024: DiaSorin completes acquisition of Luminex Corporation** DiaSorin finalized its acquisition of Luminex Corporation, strengthening its molecular diagnostic capabilities, including influenza testing technologies.
- **Q1 2025: QuidelOrtho launches Sofia Q, a next-generation rapid influenza and respiratory virus analyzer** QuidelOrtho launched Sofia Q, a new rapid analyzer for influenza and other respiratory viruses, featuring improved sensitivity and connectivity for point-of-care settings.
- **Q1 2025: BD announces expansion of BD Veritor™ Plus System for influenza testing in Asia-Pacific** BD expanded the availability of its BD Veritor™ Plus System for rapid influenza testing to several Asia-Pacific markets, aiming to improve access to point-of-care diagnostics.
- **Q2 2025: Abbott receives FDA clearance for ID NOW™ Influenza A & B 2 rapid test** Abbott received FDA clearance for its ID NOW™ Influenza A & B 2 rapid test, designed to deliver molecular results in under 15 minutes for point-of-care settings.
- **Q2 2025: Roche launches new multiplex respiratory panel including influenza A/B in Europe** Roche launched a new multiplex respiratory panel in Europe, which includes influenza A/B detection, expanding its molecular diagnostics offering for respiratory illnesses.
- **Q3 2025: QuidelOrtho secures contract with US Department of Defense for influenza diagnostic devices** QuidelOrtho was awarded a contract by the US Department of Defense to supply rapid influenza diagnostic devices for military healthcare facilities.

## **Influenza Tests Devices Market Segmentation**

### **Influenza Tests Devices Market Tests Outlook**

- Influenza Multiplex NAATs
- Influenza Antigen Tests
- Influenza Lowplex Nucleic Acid Amplification Tests (NAATs)

### **Influenza Tests Devices Market Regional Outlook**

## Market Drivers

### Rising Incidence of Influenza

The increasing incidence of influenza infections is a primary driver for the Influenza Tests Devices Market. Seasonal outbreaks of influenza lead to heightened awareness and demand for effective diagnostic tools. According to health authorities, influenza affects millions annually, resulting in significant morbidity and mortality. This persistent threat necessitates the availability of reliable testing devices to facilitate timely diagnosis and treatment. As healthcare systems strive to manage influenza outbreaks, the demand for advanced testing devices is likely to surge. The Influenza Tests Devices Market is thus positioned to benefit from this trend, as healthcare providers seek to enhance their diagnostic capabilities to combat the rising burden of influenza.

### Rising Awareness of Influenza Testing

Rising awareness of the importance of influenza testing among healthcare professionals and the general public is a significant driver for the Influenza Tests Devices Market. Educational campaigns and information dissemination have led to a better understanding of the benefits of timely diagnosis and treatment of influenza. This heightened awareness encourages individuals to seek testing when experiencing symptoms, thereby increasing demand for testing devices. Furthermore, healthcare providers are increasingly recognizing the value of accurate influenza diagnostics in managing patient care. As awareness continues to grow, the Influenza Tests Devices Market is likely to expand, driven by the need for effective testing solutions that align with public health objectives.

### Growing Focus on Preventive Healthcare

The growing emphasis on preventive healthcare is significantly influencing the Influenza Tests Devices Market. As populations become more health-conscious, there is an increasing demand for early detection and prevention strategies. Influenza testing plays a crucial role in identifying infections before they escalate, thereby reducing transmission rates. This shift towards preventive measures is supported by public health campaigns and initiatives aimed at increasing vaccination rates and promoting awareness of influenza symptoms. Consequently, the Influenza Tests Devices Market is likely to experience growth as healthcare providers invest in testing devices that facilitate early diagnosis and intervention, ultimately improving patient outcomes.

### Increased Government Initiatives and Funding

Increased government initiatives and funding for influenza surveillance and control programs are pivotal drivers for the Influenza Tests Devices Market. Governments worldwide are recognizing the importance of robust influenza monitoring systems to mitigate the impact of outbreaks. Funding for research and development of testing devices is on the rise, as authorities aim to enhance public health responses. This financial support facilitates the introduction of innovative testing technologies and expands access to diagnostic tools in underserved areas. Consequently, the Influenza Tests Devices Market stands to benefit from these initiatives, as enhanced funding translates into improved testing capabilities and greater availability of devices in the market.

### Technological Innovations in Testing Devices

Technological innovations are transforming the Influenza Tests Devices Market, leading to the development of more efficient and accurate testing solutions. Advances in molecular diagnostics, such as polymerase chain reaction (PCR) and rapid antigen tests, have enhanced the speed and reliability of influenza detection. These innovations not only improve diagnostic accuracy but also reduce the time required for results, which is critical during peak influenza seasons. The integration of digital technologies, such as telemedicine and mobile health applications, further supports the accessibility of testing devices. As a result, the Influenza Tests Devices Market is poised for growth, driven by the demand for cutting-edge diagnostic tools that meet the evolving needs of healthcare providers.

## Future Outlook

The Influenza Tests Devices Market is projected to grow at a 7.0% CAGR from 2025 to 2035, driven by technological advancements, increasing healthcare expenditure, and rising awareness of influenza diagnostics.

**New opportunities:**

- Development of rapid point-of-care testing kits for remote areas.
- Integration of AI for enhanced diagnostic accuracy and efficiency.
- Expansion into emerging markets with tailored product offerings.

By 2035, the market is expected to achieve substantial growth, positioning itself as a leader in diagnostic solutions.

## Segment Insights

### By Tests: Influenza Multiplex NAATs (Largest) vs. Influenza Antigen Tests (Fastest-Growing)

The influenza tests devices market showcases distinct segments, with Influenza Multiplex NAATs leading the way as the largest segment due to their ability to detect multiple pathogens simultaneously. As healthcare providers increasingly prioritize accurate diagnostics, this segment captures a significant share of the market, reflecting its critical role in effective disease management. Conversely, Influenza Antigen Tests are rapidly gaining traction, leveraging their cost-effectiveness and ease of use to become the fastest-growing segment. Their ability to provide quick results makes them particularly appealing in point-of-care settings.

Influenza Multiplex NAATs (Dominant) vs. Influenza Antigen Tests (Emerging)

Influenza Multiplex NAATs are recognized for their superior diagnostic accuracy, allowing for simultaneous detection of multiple influenza strains as well as other respiratory viruses. This versatility establishes them as a dominant player in the market, particularly in clinical laboratories and hospitals where comprehensive diagnostic solutions are paramount. On the other hand, Influenza Antigen Tests are emerging as essential tools in various healthcare environments, especially in primary care and emergency settings. They offer rapid results, which is crucial during influenza outbreaks, making them valuable for swift decision-making in treatment. Their growing adoption signifies a shift toward more accessible and efficient testing methods.

## Regional Market Share Analysis

### North America : Leading Market for Innovation

North America is the largest market for influenza test devices, accounting for approximately 45% of the global market share. The region's growth is driven by increasing healthcare expenditure, a high prevalence of influenza, and advancements in diagnostic technologies. Regulatory support from agencies like the FDA further catalyzes market expansion, ensuring rapid approval of innovative testing solutions. The demand for rapid and accurate testing is also on the rise, particularly in the wake of recent pandemics. The United States leads the North American market, with significant contributions from Canada. Key players such as Abbott, Thermo Fisher Scientific, and BD dominate the landscape, offering a range of advanced testing solutions. The competitive environment is characterized by continuous innovation and strategic partnerships aimed at enhancing product offerings. The presence of established healthcare infrastructure and a focus on improving patient outcomes further solidify North America's position in the influenza testing market.

### Europe : Emerging Regulatory Frameworks

Europe is witnessing significant growth in the influenza test devices market, holding approximately 30% of the global share. The region benefits from stringent regulatory frameworks that ensure high-quality standards for medical devices. The European Medicines Agency (EMA) plays a crucial role in facilitating the approval of innovative testing solutions, which is essential for addressing public health challenges. The increasing incidence of influenza and rising awareness about early diagnosis are key demand drivers in this region. Leading countries in Europe include Germany, France, and the United Kingdom, where major players like Roche and Siemens Healthineers are actively involved. The competitive landscape is marked by a mix of established companies and emerging startups, all striving to enhance diagnostic accuracy and speed. Collaborative efforts between public health organizations and private entities are also fostering innovation, making Europe a dynamic market for influenza testing devices.

### Asia-Pacific : Rapidly Growing Market Potential

Asia-Pacific is an emerging powerhouse in the influenza test devices market, accounting for about 20% of the global share. The region's growth is fueled by increasing healthcare investments, rising awareness of infectious diseases, and a growing population. Countries like China and India are witnessing a surge in demand for rapid diagnostic tests, driven by government initiatives aimed at improving healthcare access. Regulatory bodies are also becoming more supportive, streamlining approval processes for new testing technologies. China and Japan are the leading markets in this region, with significant contributions from local manufacturers and international players. The competitive landscape is characterized by a mix of established companies and innovative startups, all focused on enhancing testing capabilities. Key players such as Hologic and Cepheid are expanding their presence, contributing to the overall growth of the market in Asia-Pacific. The region's potential for growth is substantial, making it a focal point for investment in influenza testing solutions.

### Middle East and Africa : Untapped Market Opportunities

The Middle East and Africa region is gradually emerging in the influenza test devices market, holding approximately 5% of the global share. The growth is driven by increasing healthcare investments and a rising awareness of infectious diseases. Governments are focusing on improving healthcare infrastructure, which is essential for enhancing diagnostic capabilities. The demand for influenza testing is expected to rise, particularly in response to public health initiatives aimed at controlling outbreaks. Leading countries in this region include South Africa and the UAE, where there is a growing presence of both local and international players. The competitive landscape is evolving, with companies looking to establish partnerships and collaborations to enhance their market presence. Key players are beginning to invest in the region, recognizing the untapped potential for growth in influenza testing solutions. As healthcare systems continue to develop, the market is poised for significant expansion.

## Competitive Benchmarking

The Influenza Tests Devices Market is currently characterized by a dynamic competitive landscape, driven by the increasing demand for rapid and accurate diagnostic solutions. Key players such as Abbott (US), Roche (CH), and Thermo Fisher Scientific (US) are at the forefront, leveraging innovation and strategic partnerships to enhance their market presence. Abbott (US) has focused on expanding its product portfolio with advanced molecular testing solutions, while Roche (CH) emphasizes its commitment to research and development, aiming to introduce next-generation testing devices. Thermo Fisher Scientific (US) appears to be concentrating on regional expansion, particularly in emerging markets, to capitalize on the growing need for influenza diagnostics. Collectively, these strategies contribute to a competitive environment that is increasingly centered around technological advancement and market responsiveness.In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and reduce costs. The market structure is moderately fragmented, with several players vying for market share. This fragmentation allows for a diverse range of products and innovations, although it also intensifies competition among key players. The collective influence of these companies shapes the market dynamics, as they strive to differentiate themselves through unique offerings and strategic initiatives.

In August  Roche (CH) announced a collaboration with a leading biotechnology firm to develop a novel influenza test that integrates artificial intelligence for improved diagnostic accuracy. This strategic move is significant as it not only enhances Roche's product capabilities but also positions the company as a leader in the integration of AI technology within diagnostic devices. Such innovations are likely to set new benchmarks in the industry, influencing competitors to adopt similar approaches.

In September  Abbott (US) launched a new rapid influenza test that provides results in under 15 minutes, significantly reducing the time to diagnosis. This development is crucial as it addresses the urgent need for timely testing, particularly in high-risk populations. Abbott's focus on speed and efficiency may compel other companies to accelerate their own product development timelines, thereby intensifying competition in the rapid testing segment.

In October  Thermo Fisher Scientific (US) unveiled a strategic partnership with a major healthcare provider to enhance the distribution of its influenza testing devices across North America. This partnership is indicative of a broader trend towards collaboration in the healthcare sector, as companies seek to leverage each other's strengths to improve market access and customer engagement. Such alliances are likely to reshape the competitive landscape, fostering a more interconnected ecosystem of diagnostic solutions.

As of October  the competitive trends in the Influenza Tests Devices Market are increasingly defined by digitalization, sustainability, and the integration of advanced technologies such as AI. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex market challenges. Looking ahead, competitive differentiation is expected to evolve, with a shift from traditional price-based competition towards a focus on innovation, technological advancements, and supply chain reliability. This transition may ultimately redefine the parameters of success in the influenza diagnostics sector.

## Recent News & Developments

- **Q2 2024: QuidelOrtho receives FDA clearance for Sofia 2 SARS Antigen FIA for use with nasal swab specimens** QuidelOrtho announced FDA clearance for its Sofia 2 SARS Antigen FIA, which can be used for rapid detection of influenza and SARS-CoV-2 from nasal swab specimens, expanding its diagnostic portfolio.
- **Q2 2024: Roche launches cobas® Influenza A/B & RSV test on the cobas® Liat® System in the US** Roche introduced its new cobas® Influenza A/B & RSV test for the cobas® Liat® System, providing rapid molecular results for influenza and RSV, aimed at improving point-of-care diagnostics in the US.
- **Q2 2024: BD Receives CE Mark for BD MAX™ Influenza A/B Test** BD (Becton, Dickinson and Company) received CE Mark approval for its BD MAX™ Influenza A/B test, enabling broader European market access for its molecular diagnostic platform.
- **Q3 2024: Abbott launches Alinity m Resp-4-Plex assay for detection of SARS-CoV-2, influenza A/B, and RSV** Abbott announced the launch of its Alinity m Resp-4-Plex assay, a multiplex molecular test that simultaneously detects SARS-CoV-2, influenza A/B, and RSV, expanding its respiratory diagnostics portfolio.
- **Q3 2024: QuidelOrtho announces partnership with CDC for influenza surveillance using rapid diagnostic tests** QuidelOrtho entered a partnership with the CDC to provide rapid influenza diagnostic tests for national surveillance programs, aiming to improve real-time tracking of flu outbreaks.
- **Q4 2024: Roche opens new diagnostics manufacturing facility in Indianapolis** Roche Diagnostics inaugurated a new manufacturing facility in Indianapolis to increase production capacity for its influenza and respiratory diagnostic test kits.
- **Q4 2024: DiaSorin completes acquisition of Luminex Corporation** DiaSorin finalized its acquisition of Luminex Corporation, strengthening its molecular diagnostic capabilities, including influenza testing technologies.
- **Q1 2025: QuidelOrtho launches Sofia Q, a next-generation rapid influenza and respiratory virus analyzer** QuidelOrtho launched Sofia Q, a new rapid analyzer for influenza and other respiratory viruses, featuring improved sensitivity and connectivity for point-of-care settings.
- **Q1 2025: BD announces expansion of BD Veritor™ Plus System for influenza testing in Asia-Pacific** BD expanded the availability of its BD Veritor™ Plus System for rapid influenza testing to several Asia-Pacific markets, aiming to improve access to point-of-care diagnostics.
- **Q2 2025: Abbott receives FDA clearance for ID NOW™ Influenza A & B 2 rapid test** Abbott received FDA clearance for its ID NOW™ Influenza A & B 2 rapid test, designed to deliver molecular results in under 15 minutes for point-of-care settings.
- **Q2 2025: Roche launches new multiplex respiratory panel including influenza A/B in Europe** Roche launched a new multiplex respiratory panel in Europe, which includes influenza A/B detection, expanding its molecular diagnostics offering for respiratory illnesses.
- **Q3 2025: QuidelOrtho secures contract with US Department of Defense for influenza diagnostic devices** QuidelOrtho was awarded a contract by the US Department of Defense to supply rapid influenza diagnostic devices for military healthcare facilities.

## Report Scope

| MARKET SIZE 2024 | 0.4387(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 0.4694(USD Billion) |
| MARKET SIZE 2035 | 0.9236(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 7.0% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Abbott (US), Roche (CH), Thermo Fisher Scientific (US), BD (US), Siemens Healthineers (DE), QuidelOrtho (US), Hologic (US), Cepheid (US), BioMerieux (FR) |
| Segments Covered | Tests, Region |
| Key Market Opportunities | Integration of rapid testing technologies enhances diagnostic accuracy in the Influenza Tests Devices Market. |
| Key Market Dynamics | Rising demand for rapid diagnostic tests drives innovation and competition in the influenza testing devices market. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Influenza Tests Devices Market?**
A: As of 2024, the market valuation stands at 0.4387 USD Billion.

**Q: What is the projected market size for the Influenza Tests Devices Market in 2035?**
A: The market is projected to reach 0.9236 USD Billion by 2035.

**Q: What is the expected CAGR for the Influenza Tests Devices Market from 2025 to 2035?**
A: The market is expected to grow at a CAGR of 7.0% during the forecast period.

**Q: Which companies are the key players in the Influenza Tests Devices Market?**
A: Key players include Abbott, Roche, Thermo Fisher Scientific, BD, Siemens Healthineers, QuidelOrtho, Hologic, Cepheid, and BioMerieux.

**Q: What are the main segments within the Influenza Tests Devices Market?**
A: The main segments include Influenza Multiplex NAATs, Influenza Antigen Tests, and Influenza Lowplex Nucleic Acid Amplification Tests (NAATs).

**Q: What was the market size for Influenza Multiplex NAATs in 2024?**
A: In 2024, the market size for Influenza Multiplex NAATs was 0.175 USD Billion.

**Q: What is the projected market size for Influenza Antigen Tests by 2035?**
A: The market for Influenza Antigen Tests is projected to reach 0.3 USD Billion by 2035.

**Q: How did the market for Influenza Lowplex NAATs perform in 2024?**
A: The market for Influenza Lowplex NAATs was valued at 0.1137 USD Billion in 2024.

**Q: What trends are influencing the growth of the Influenza Tests Devices Market?**
A: The growth appears to be driven by advancements in testing technology and increasing demand for rapid diagnostic solutions.

**Q: How does the performance of the Influenza Tests Devices Market compare across its segments?**
A: The Influenza Multiplex NAATs segment shows the highest growth potential, followed by Influenza Antigen Tests and Influenza Lowplex NAATs.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/influenza-tests-devices-market-16090*